论文部分内容阅读
卵巢癌起病隐匿、缺乏早期诊断手段、预后不良，严重威胁女性健康。而传统的手术及化疗治疗远期疗效不理想。近年来，与卵巢癌相关的信号转导通路研究不断深入，卵巢癌的靶向治疗研究逐渐展开。其中表皮生长因子受体（EGFR）及其下游因子多瘤促活化因子3（PEA3）在卵巢癌的发生及浸润转移中起到重要作用，针对其通路的靶向治疗药物逐步投入临床试验，并取得一定的疗效。该文将就EGFR、PEA3在卵巢癌病理机制中的作用及相应的靶向治疗研究进行综述。“,”Because of lacking of early symptoms,early detection methods and unfavourable prognosis, ovarian cancer is a leading threat to women′s health.However,conventional surgery treatment and chemother-apy do not have satisfactory long-term effect.In recent years,along with the continuous deepening of the study on ovarian cancer related signal pathways,targeted agents treatment have been developed.Epidermal growth factor receptor (EGFR) and polyoma enhancer activator 3 (PEA3) are well studied which play important roles in the pathogenesis and metastasis of ovarian cancer.Their specific inhibitors have shown benefits in clinical trials during the past few years.Here is to make a review of the role of EGFR and PEA3 in the patho-genesis of ovarian cancer and the related targeted therapies .